Sanofi (SNY) Receivables (2009 - 2025)

Sanofi has disclosed Receivables across 17 years of filings, most recently posting $10.5 billion for Q4 2025.

• Receivables for Q4 2025 came in at $10.5 billion, up 24.69% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.5 billion (up 24.69% YoY), and the FY2025 annual result was $10.5 billion, up 24.69% from the prior year.
• Receivables came in at $10.5 billion for Q4 2025 at Sanofi, up from $8.8 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $10.6 billion in Q4 2023 to a low of $8.2 billion in Q2 2021.
• The 5-year median for Receivables is $9.0 billion (2022), against an average of $9.2 billion.
• Across the five-year window, Receivables declined 20.99% in 2024 and advanced 24.69% in 2025, its largest moves.
• Sanofi's Receivables stood at $9.6 billion in 2021, then declined by 6.76% to $8.9 billion in 2022, then advanced by 19.04% to $10.6 billion in 2023, then slipped by 20.99% to $8.4 billion in 2024, then rose by 24.69% to $10.5 billion in 2025.
• The last three Receivables figures came in at $10.5 billion (Q4 2025), $8.8 billion (Q2 2025), and $8.4 billion (Q4 2024), per Business Quant data.